Survivin expression in head and neck squamous cell carcinomas is frequent and correlates with clinical parameters and treatment outcomes.
Head and neck squamous cell carcinoma (HNSCC)
Prognosis
Survivin
Journal
Clinical oral investigations
ISSN: 1436-3771
Titre abrégé: Clin Oral Investig
Pays: Germany
ID NLM: 9707115
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
16
08
2017
accepted:
12
04
2018
pubmed:
20
4
2018
medline:
7
6
2019
entrez:
20
4
2018
Statut:
ppublish
Résumé
Strong expression of survivin is associated with worse survival in many different tumours, and in cell culture, a correlation between radiation resistance and survivin expression can be seen. The potential of survivin expression as a prognostic/predictive marker or therapeutic target has not been examined in head and neck squamous cell carcinomas (HNSCC) yet. Retrospective study of 452 tissue samples and clinical data from patients with squamous cell carcinomas of the larynx/hypopharynx (LSCC), oral cavity (OSCC) and oropharynx (OPSCC) treated in the University Medical Centre Hamburg-Eppendorf between 2002 and 2006. The expression patterns were detected by tissue microarray technique and correlated with clinical parameters (sex, age, tumour location, TNM 7th edition, grading, recurrence-free and overall survival). 222 OSCC, 126 OPSCC and 105 LSCC tumours of 118 females and 335 males with a mean follow-up of 41.3 months were examined. Survivin expression correlates with pN, cM, pT and overall survival. The potential of survivin as a prognostic/predictive marker is very high. The findings have to be confirmed in a larger cohort of HNSCC esp. in those tumours treated primarily with radio/radiochemotherapy.
Identifiants
pubmed: 29671054
doi: 10.1007/s00784-018-2444-8
pii: 10.1007/s00784-018-2444-8
doi:
Substances chimiques
Biomarkers, Tumor
0
Survivin
0
Types de publication
Journal Article
Langues
eng
Pagination
361-367Références
Cancer Res. 1999 Feb 15;59(4):803-6
pubmed: 10029066
Head Neck. 2002 Feb;24(2):165-80
pubmed: 11891947
Eur J Cancer. 2002 Nov;38(17):2316-24
pubmed: 12441269
Head Neck. 2004 Aug;26(8):733-40
pubmed: 15287041
Nat Rev Cancer. 2005 Feb;5(2):127-35
pubmed: 15685196
Int J Exp Pathol. 2005 Dec;86(6):347-63
pubmed: 16309541
Mol Cancer Ther. 2006 May;5(5):1087-98
pubmed: 16731740
Clin Cancer Res. 2006 Oct 1;12(19):5726-32
pubmed: 17020977
Anticancer Res. 2006 Sep-Oct;26(5B):3813-7
pubmed: 17094406
J Dent Res. 2007 Feb;86(2):104-14
pubmed: 17251508
Clin Cancer Res. 2007 Mar 15;13(6):1749-56
pubmed: 17363528
Int J Oral Maxillofac Surg. 2007 Jul;36(7):632-9
pubmed: 17566705
Int J Cancer. 2007 Sep 15;121(6):1169-74
pubmed: 17617794
Clin Cancer Res. 2008 Aug 15;14(16):5000-5
pubmed: 18698017
Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
APMIS. 2009 Mar;117(3):162-75
pubmed: 19245589
Acta Otolaryngol. 2010;130(1):4-9
pubmed: 19322702
Head Neck. 2009 Aug;31(8):1039-48
pubmed: 19340865
Radiother Oncol. 2010 Aug;96(2):267-73
pubmed: 20638740
Clin Cancer Res. 2010 Aug 15;16(16):4113-25
pubmed: 20682707
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Ginekol Pol. 2012 Jul;83(7):537-40
pubmed: 22880480
Int J Cancer. 2013 Oct 15;133(8):1994-2003
pubmed: 23564498
Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Jun;117(6):733-42
pubmed: 24726415
J Urol. 2015 Jul;194(1):230-7
pubmed: 25681288
Mol Med Rep. 2015 Jul;12(1):601-8
pubmed: 25707849
BMC Cancer. 2015 May 22;15:425
pubmed: 25998617
Cell Death Dis. 2015 May 28;6:e1771
pubmed: 26018732
Acta Histochem. 2015 Jul;117(6):590-4
pubmed: 26095032
Indian J Med Res. 2015 Apr;141(4):389-97
pubmed: 26112839
Biomacromolecules. 2015 Jul 13;16(7):2168-78
pubmed: 26120930
J Cosmet Dermatol. 2015 Sep;14(3):191-203
pubmed: 26177774
Oncogene. 2016 Apr 21;35(16):2087-97
pubmed: 26234674
Radiother Oncol. 2016 Feb;118(2):359-68
pubmed: 26747757
Int J Cancer. 1988 Feb 15;41(2):184-97
pubmed: 3338870
Nat Med. 1997 Aug;3(8):917-21
pubmed: 9256286
Cancer. 1997 Nov 1;80(9):1803-4
pubmed: 9351551
Cancer Res. 1998 May 1;58(9):1808-12
pubmed: 9581817